Profile data is unavailable for this security.
About the company
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. OPERA co-opts the cell’s natural process with its synthetic oligo and catalyzes a single base change to modify protein sequence and function without the need to permanently modify one’s genome. The Company's focus areas include the liver and central nervous system (CNS).
- Revenue in USD (TTM)0.00
- Net income in USD-81.17m
- Incorporated2014
- Employees101.00
- LocationKorro Bio IncOne Kendall Square. Building 600-700Suite 6-401CAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 468-1999
- Fax+1 (302) 636-5454
- Websitehttps://www.korrobio.com/
More ▼
Mergers & acquisitions
| Acquired company | KRRO:NAQ since announced | Transaction value |
|---|---|---|
| Korro Bio Inc | 155.00% | -- |
Data delayed at least 15 minutes, as of May 10 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PepGen Inc | 0.00 | -78.63m | 453.79m | 64.00 | -- | 3.08 | -- | -- | -3.30 | -3.30 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -43.62 | -- | -48.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Larimar Therapeutics Inc | 0.00 | -36.95m | 454.26m | 42.00 | -- | 3.83 | -- | -- | -0.8416 | -0.8416 | 0.00 | 1.86 | 0.00 | -- | -- | 0.00 | -33.24 | -42.22 | -36.56 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
| Theravance Biopharma Inc | 57.42m | -55.19m | 455.49m | 99.00 | -- | 2.12 | -- | 7.93 | -0.9704 | -0.9704 | 1.04 | 4.43 | 0.1161 | -- | 3.35 | 580,040.40 | -11.16 | -40.51 | -11.79 | -48.50 | -- | -- | -96.11 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Voyager Therapeutics Inc | 250.01m | 132.33m | 459.04m | 162.00 | 2.85 | 1.57 | 3.36 | 1.84 | 2.96 | 2.96 | 5.56 | 5.37 | 0.9792 | -- | 5.97 | 1,543,259.00 | 51.83 | 0.6378 | 70.85 | 0.8203 | -- | -- | 52.93 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -33.76m | 459.42m | 19.00 | -- | 4.66 | -- | -- | -6.97 | -6.97 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.06 | -86.84 | -49.24 | -130.46 | -- | -- | -- | -769.76 | -- | -15.43 | 0.1179 | -- | -- | -- | -5.33 | -- | -- | -- |
| ACELYRIN Inc | 0.00 | -381.64m | 462.91m | 130.00 | -- | 0.6978 | -- | -- | -10.84 | -10.84 | 0.00 | 6.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Fulcrum Therapeutics Inc | 2.81m | -97.34m | 464.29m | 76.00 | -- | 1.97 | -- | 165.52 | -1.59 | -1.59 | 0.0458 | 3.80 | 0.0116 | -- | 1.68 | 36,907.89 | -40.19 | -50.55 | -42.88 | -55.91 | -- | -- | -3,470.05 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Fate Therapeutics Inc | 6.48m | -190.05m | 464.37m | 181.00 | -- | 1.09 | -- | 71.68 | -1.92 | -1.92 | 0.0653 | 3.74 | 0.0108 | -- | 0.9024 | 35,790.05 | -31.67 | -31.82 | -34.36 | -36.05 | -- | -- | -2,933.79 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Allogene Therapeutics Inc | 95.00k | -327.27m | 471.20m | 232.00 | -- | 0.9087 | -- | 4,959.96 | -2.09 | -2.09 | 0.0006 | 3.04 | 0.0001 | -- | -- | 409.48 | -44.70 | -28.46 | -47.65 | -30.21 | -- | -- | -344,489.50 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| Korro Bio Inc | 0.00 | -81.17m | 472.91m | 101.00 | -- | 2.41 | -- | -- | -68.38 | -68.38 | 0.00 | 21.20 | 0.00 | -- | -- | 0.00 | -47.34 | -31.55 | -53.69 | -36.48 | -- | -- | -- | -365.87 | -- | -- | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| Travere Therapeutics Inc | 155.72m | -415.73m | 479.49m | 380.00 | -- | 6.47 | -- | 3.08 | -5.32 | -2.00 | 2.04 | 0.9732 | 0.2116 | 1.57 | 7.04 | 409,800.00 | -56.49 | -36.95 | -71.19 | -44.77 | 94.34 | 95.92 | -266.96 | -165.79 | 2.75 | -- | 0.836 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Adlai Nortye Ltd (ADR) | 5.00m | -104.87m | 481.55m | 127.00 | -- | 6.06 | -- | 96.31 | -7.26 | -7.26 | 0.1931 | 2.15 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -2,097.42 | -- | -- | -1.69 | 0.2843 | -- | -- | -- | -78.38 | -- | -- | -- |
| Entrada Therapeutics Inc | 162.87m | 23.49m | 482.94m | 160.00 | 22.86 | 1.79 | 18.03 | 2.97 | 0.6273 | 0.6273 | 4.79 | 8.02 | 0.3302 | -- | 3.89 | 1,024,359.00 | 4.76 | -- | 7.06 | -- | -- | -- | 14.42 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| Third Harmonic Bio Inc | 0.00 | -30.82m | 484.50m | 30.00 | -- | 1.77 | -- | -- | -0.9461 | -0.9461 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -10.70 | -- | -10.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
| Shattuck Labs Inc | 2.72m | -85.08m | 495.48m | 75.00 | -- | 3.84 | -- | 182.50 | -1.93 | -1.93 | 0.0608 | 2.71 | 0.0168 | -- | -- | 36,200.00 | -52.52 | -29.14 | -57.94 | -32.42 | -- | -- | -3,133.63 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
Data as of May 10 2024. Currency figures normalised to Korro Bio Inc's reporting currency: US Dollar USD
47.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 727.21k | 7.84% |
| Deep Track Capital LPas of 26 Apr 2024 | 714.29k | 7.70% |
| Eventide Asset Management LLCas of 31 Dec 2023 | 546.33k | 5.89% |
| Point72 Asset Management LPas of 31 Dec 2023 | 542.66k | 5.85% |
| Citadel Advisors LLCas of 31 Dec 2023 | 529.17k | 5.71% |
| Cormorant Asset Management LPas of 31 Dec 2023 | 529.17k | 5.71% |
| Invus Public Equities Advisors LLCas of 31 Dec 2023 | 418.61k | 4.52% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 264.94k | 2.86% |
| Monashee Investment Management LLCas of 31 Dec 2023 | 90.81k | 0.98% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 79.71k | 0.86% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
